• 1. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 4. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 5. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Comprehensive Overview of 1-[(1,2-oxazol-3-yl)methyl]piperazine (CAS No. 885952-54-5): Properties, Applications, and Industry Insights

1-[(1,2-oxazol-3-yl)methyl]piperazine (CAS No. 885952-54-5) is a heterocyclic compound that has garnered significant attention in pharmaceutical and chemical research due to its unique structural features and versatile reactivity. The compound combines a piperazine ring with a 1,2-oxazole moiety, making it a valuable intermediate for drug discovery and material science applications. Its molecular formula, C₈H₁₃N₃O, and molecular weight of 167.21 g/mol reflect its compact yet functionally rich architecture.

In recent years, the demand for piperazine derivatives like 1-[(1,2-oxazol-3-yl)methyl]piperazine has surged, driven by their role in developing central nervous system (CNS) therapeutics and antimicrobial agents. Researchers are particularly interested in its potential as a scaffold for kinase inhibitors and GPCR modulators, aligning with trends in personalized medicine and targeted therapies. The compound's CAS No. 885952-54-5 is frequently searched in academic databases, underscoring its relevance in modern organic synthesis.

The synthesis of 1-[(1,2-oxazol-3-yl)methyl]piperazine typically involves N-alkylation of piperazine with a 3-(chloromethyl)-1,2-oxazole precursor, followed by purification via chromatography or crystallization. Its physicochemical properties—such as a melting point range of 80–85°C and solubility in polar organic solvents—make it compatible with standard laboratory protocols. These characteristics are critical for formulators optimizing drug delivery systems or bioconjugation techniques.

From an industrial perspective, 885952-54-5 is often discussed in contexts like green chemistry and process optimization. Companies are exploring catalytic methods to reduce waste generation during its production, responding to the global push for sustainable chemical manufacturing. Additionally, its patent landscape reveals applications in neurodegenerative disease research, with several filings linking it to Alzheimer's disease biomarkers and Parkinson's disease models.

Analytical techniques for characterizing 1-[(1,2-oxazol-3-yl)methyl]piperazine include HPLC-MS, NMR spectroscopy, and X-ray crystallography. These methods confirm its high purity (>98%), a key requirement for preclinical studies. The compound's stability under ambient conditions also facilitates its use in high-throughput screening platforms, where reproducibility is paramount.

Emerging discussions in online forums highlight queries about the compound's structure-activity relationships (SAR) and toxicological profiles. While current data suggests low acute toxicity, ongoing studies aim to elucidate its metabolic pathways—a hot topic given the rise of computational ADMET prediction tools. Such insights are vital for researchers comparing it to analogous azolyl-piperazine compounds in virtual screening workflows.

In summary, CAS No. 885952-54-5 represents a compelling case study in medicinal chemistry innovation. Its dual functionality as a hydrogen bond acceptor and lipophilic fragment positions it at the intersection of multiple therapeutic areas. As AI-driven de novo drug design gains traction, this compound's modularity ensures its continued prominence in peer-reviewed literature and industrial R&D pipelines alike.

• 855741-77-4(3-Isoxazolemethanamine,N,N-diethyl-)
• 1187933-48-7((1,2-oxazol-3-yl)methanamine hydrochloride)
• 173850-40-3(1-(Isoxazol-3-yl)-N,N-dimethylmethanamine)
• 2470-12-4(3-Isoxazolemethanamine,N,5-dimethyl-N-2-propyn-1-yl-)
• 297172-17-9(methyl(1,2-oxazol-3-yl)methylamine)
• 173850-51-6(1-(5-methylisoxazol-3-yl)methylpiperazine)
• 1187927-38-3(methyl[(1,2-oxazol-3-yl)methyl]amine hydrochloride)
• 886851-25-8(methyl(5-methyl-1,2-oxazol-3-yl)methylamine)
• 131052-58-9(1,2-oxazol-3-ylmethanamine)
• 204012-86-2(3-(piperazin-1-ylmethyl)benzo[d]isoxazole)